Board summary
Key figures
48,666
Registered population
57.6% aged 18–64
20.7%
Aged 65+
ICB 19.9% · England 17.9%
5.3%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
53.1%
In IMD quintile 1
ICB 17.1% · England 21.0%
~23,415
Core20 residents (est.)
Resident basis; registered basis ~25,563 · see page 3
8,508
Hypertension register
+2.91% in 3 yrs · England +5.60%
393
SMI register
32.8% of Swale's
1,375
COPD register
Reviews +4.86% in 3 yrs
Forecast to 2030
9,685
Hypertension patients, 2030
+1,177 on today
81.0%
QRISK ≥20% on statins, 2030
+5.74pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review shortfall alongside high prescribing.
Annual reviews fell 4.9% to 64.0% over 2023 to 2025 (England +4.4%), leaving 1,072 patients unreviewed while age 5-19 prescribing is 2,114 per 1,000.
Under-80 blood pressure control falling.
Under-80 blood pressure control fell 4.1% (-3.0 pp) to 70.5% over 2023 to 2025 while England rose +3.2% (+2.1 pp), suggesting possible recall drift.
Older-adult BP and heart failure reviews.
Over 2023 to 2025, 80+ blood pressure control rose +6.0% to 80.0% (England +2.2%) and heart failure reviews rose +17.1% to 75.1% (England +8.7%).
Population, age and ethnicity
Higher shares of children and older adults are consistent with dual-end primary care demand
Sheppey PCN has 48,666 registered patients. Children aged 0–17 represent 21.8% (10,591 patients; Swale 22.0%, ICB 20.7%, England 19.6%) and adults aged 65+ represent 20.7% (10,056; Swale 18.2%, ICB 19.9%, England 17.9%), leaving 57.6% aged 18–64 (Swale 59.8%, ICB 59.5%, England 62.7%). Projected list growth to 2030 is 5.8% (Swale 5.5%, ICB 6.0%, England 2.3%) under an unverified method. On Census resident figures, not registered ethnicity, 94.7% are White (Swale 93.8%, ICB 88.6%, England 81.1%), with a 5.3% ethnic minority share and 0.7% Gypsy or Irish Traveller residents (Swale 0.6%, ICB 0.3%, England 0.1%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Swale local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Swale LA) | 1,484 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Swale LA) | 686 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Swale LA) | 19.1 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 53.1%, spanning 32.8 percentage points between practices
In Sheppey PCN, 53.1% of registered patients live in Core20 areas, exceeding Swale (25.7%), NHS Kent and Medway ICB (17.1%) and England (21.0%), with an average IMD decile of 2.8 (England 5.5). Weighted practice share is 52.5% (a 0.57 pp difference). Practice concentration spans 32.8 pp, led by St Georges Medical Centre (67.17%) and Sheerness Health Centre (61.4%). By volume, St Georges Medical Centre has 7,199 estimated Core20 patients, while Sheppey Healthy Living Centre holds 4,944 despite its lower 34.36% share, requiring dual-track targeting by concentration and scale.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
393
SMI register
0.81% recorded prevalence
375
Learning disability register
0.77% recorded prevalence
14
Care homes, 282 beds
In the PCN catchment
9.9%
Provide unpaid care
Swale, Census 2021
The PCN records 375 patients on its learning disability register (0.8% prevalence; Swale 0.8%, ICB 0.6%, England 0.6%) and 393 on its severe mental illness register (0.8%; Swale 0.8%, ICB 0.9%, England 1.0%). Catchment capacity covers 14 care homes with 282 beds.
Severe mental illness: physical health checks
Across 393 SMI register patients (0.8% prevalence vs England 1.0%), 12-month BMI checks fell 4.2 pp over 2023 to 2025 to 76.2% (England 82.1%, +5.1 pp), while blood pressure checks reached 80.7% (England 83.4%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,508
Hypertension register
+2.91%
Register growth, 3 yrs
Swale +5.38% · England +5.60%
−3.02pp
BP control, under 80
≤140/90 · +4.56pp aged 80+
+1,177
More patients by 2030
Forecast 9,685 (18.47%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.4% (8,508 patients), compared with 17.0% in Swale, 16.2% in NHS Kent and Medway ICB and 15.2% in England, with register growth of +2.9% over 2023 to 2025 (England +5.6%). Blood pressure control in patients aged under 80 is 70.5% (England 67.8%), but fell 3.0 pp (relative change -4.1%; England +2.1 pp, +3.2%) over 2023 to 2025. For patients aged 80 and over, control rose +4.6 pp (+6.0%; England +1.8 pp, +2.2%) to 80.0% (England 81.2%). The three-year decline in under-80 control may reflect recall or treatment review intervals, which clinical audit would test.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy reached 67.9%, above Swale (64.2%), NHS Kent and Medway ICB (61.4%) and England (63.6%), after rising +9.2% over 2023 to 2025 (England +6.2%). Favourable treatment rates provide an opportunity to review adherence across at-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 111,707 | £2.10 | £1.90 | £1.86 | £234,585 |
| Cardiovascular (all), 2025 | 132,495 | £2.10 | £3.57 | £3.33 | £278,240 |
Lipid-regulating drugs cost £2.10 per item across 111,707 items in 2026, compared with £2.32 in Swale, £1.90 in NHS Kent and Medway ICB and £1.86 in England. The PCN spends £26,810 more than at England's unit cost. Unit-cost differences reflect formulary choice and do not establish prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−4.86%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.88%
Asthma prevalence, PCN 3-yr % change
Asthma prescribing for ages 5–19 is 2,114 items per 1,000 (England 1,488, Swale 1,582), while recorded reviews fell 4.9% over 2023 to 2025 to 64.0% (England 65.7%, +4.4%), leaving about 1,100 patients (1,072) unreviewed across the 2,977-patient register. COPD prevalence is 2.8% (1,375 patients; England 1.9%) with 80.6% reviewed in the last 12 months (England 76.4%). Higher paediatric prescribing alongside falling reviews may indicate reactive care, which clinical review audits could test.
Cancer register and children's immunisation
The cancer register records 2,010 patients (4.1% prevalence vs England 3.8%). In Q1 2025/26 COVER data, 6-in-1 at 24 months achieved 95.3% (England 92.2%), but age-5 second-dose MMR dropped to 85.5% despite 94.2% receiving MMR1, creating an 8.7 pp booster gap. At The Om Medical Centre, MMR2 trails MMR1 by 20 pp, and by 18.5 pp at Vel Surgery, showing that booster recall requires focused practice intervention.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of staged cancers in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384 known-stage cases; England 55.3%), 19.4 pp below the 75.0% national ambition by 2028. Staging reflects system pathways rather than PCN performance; only 63.6% of 13,189 registered cancers had a known stage (England 67.0%). Reaching 75% requires 1,627 extra early-stage diagnoses across the ICB. Locally, PCN cervical screening is 70.5% (Swale 72.0%), trailing at The Om Medical Centre (61.2%), while breast screening is 67.9% (England 69.9%). Targeting screening recall at practices with lower uptake provides primary care's main lever to aid earlier detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, Medway NHS Foundation Trust achieved 81.6% on the cancer 62-day referral to treatment standard, 3.4 pp below the 85.0% standard but above England (71.2%) and NHS Kent and Medway Integrated Care Board (75.9%), while Maidstone and Tunbridge Wells NHS Trust reached 87.4% and Mid and South Essex NHS Foundation Trust recorded 50.2%. Medway met the 75.0% 28-day faster diagnosis standard at 77.8% (ICB 76.8%, England 79.3%) and the 96.0% 31-day standard at 99.6% (ICB 95.8%, England 92.5%). Diagnostic 6+ week waits at Medway were 0.7% for MRI and 0.0% for CT.
| Pathways within standard (%) | Medway | Mid and South Essex | Maidstone and Tunbridge Wells | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 67.45 | 81.78 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 81.88 | 98.35 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 50.25 | 87.43 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Mid and South Essex | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 0.68 | 23.35 | 0.92 | 21.40 |
| CT | 0.00 | 6.07 | 0.51 | 9.92 |
| Echocardiography | 36.62 | 65.05 | 2.57 | 28.48 |
| Colonoscopy | 1.88 | 64.09 | 19.80 | 30.83 |
| Gastroscopy | 3.32 | 59.76 | 24.03 | 29.02 |
| All 15 DM01 tests | 14.20 | 41.54 | 6.42 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In provisional June 2026 figures, adults aged 65 and over accounted for 65.8% of all community contacts among Swale borough residents (138,250 of 210,170 contacts). These resident figures describe wider community service activity rather than PCN-specific delivery.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Vel Surgery | 111 | 60.6 | 84.8% | 82.0% | 89.0% |
| Sheppey Healthy | 113 | 34.4 | 32.3% | 66.5% | 71.5% |
| Om | 110 | 48.2 | 50.8% | 65.6% | 65.1% |
| St Georges | 107 | 67.2 | 21.6% | 68.8% | 62.7% |
| Sheerness | 97 | 61.4 | 28.1% | 73.8% | 58.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 tracked measures trail England's three-year trajectory across Sheppey PCN
Across 25 tracked measures, 13 trail England's three-year trajectory over 2023 to 2025. Severe mental illness BMI recording fell 4.2 pp to 76.2% (England +5.1 pp), while asthma reviews fell 4.9% to 64.0% (England +4.4%). Dementia recorded prevalence fell 1.7% to 0.6% (England +6.0%). Conversely, key strengths showed progress: heart failure annual reviews rose +17.1% to 75.1% (England +8.7%), and breast screening coverage rose +28.3% over 2023 to 2024 to 67.9% (England +8.4%). These diverging paths may reflect differing local recall practices across conditions, to test through clinical audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
BMI record (SMI)
Dementia register
BP control, under 80
Hypertension treated to target
Breast screening (53-70)
Heart failure reviews
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Swale | Asset | PCN | Swale |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (282 beds) | n/a | Schools (catchment) | 25 | n/a |
| Children's centres | 4 | 10 | Places of worship | 12 | 70 |
| Libraries | 2 | 5 | Food banks (VCS) | 1 | 5 |
| Day centres (VCS) | 8 | 9 | Children and young people (VCS) | 3 | 20 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 2 | 15 |
| Primary academies | 8 | 31 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Asthma reviews reached 64.0% of 2,977 patients (Swale 63.4%, England 65.7%), falling 4.9% (3.3 pp) over 2023 to 2025 (England +4.4%, +2.8 pp) and leaving 1,072 unreviewed alongside 2,114 items per 1,000 aged 5-19 (England 1,488). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension recall and titration review
Across 8,508 hypertensive patients, under-80 BP control is 70.5% (Swale 67.8%, England 67.8%) but fell 4.1% (3.0 pp) over 2023 to 2025 (England +3.2%, +2.1 pp); recent readings are 87.8% (down 0.6%; England 90.0%, +3.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Dementia register coding and case-finding audit
Dementia recorded prevalence is 0.6% (290 patients) against 0.7% in Swale and 0.8% in ICB and England, falling 1.7% over 2023 to 2025 (Swale +2.4%, England +6.0%), giving a crude benchmark range of +50 to +91 patients. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health and dual-track planning (p2) | Gypsy or Irish Traveller | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Dual-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Under-eighty blood pressure recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension recall and titration review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Dementia register coding and case-finding audit (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
